Tag: director

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.

CRANSTON, Rhode Island, July 25, 2025 (GLOBE NEWSWIRE) -- Nelipak^® Corporation (“Nelipak®”), un proveedor líder global de soluciones de empaque para el sector de salud para dispositivos médicos, diagnóstico, administración farmacéutica y otras aplicaciones exigentes, anunció que ha iniciado oficialmente la construcción de su nueva planta de producción de vanguardia en el Valle Verde de Costa Rica, en Alajuela. La ceremonia de colocación de la primera piedra marca un hito importante en la continua inversión de Nelipak en Costa Rica y su compromiso de apoyar el creciente ecosistema de fabricación de dispositivos médicos en la región.

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

Revenue Growth of 17.6% to HK$78.7 Million (US$10.1 million); Strong Cash Position of HK$84.9 Million (US$10.9 million)

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- The ADVERTISING Club of New York, the industry's leading professional organization representing the advertising, media, marketing, and ad-tech industries is pleased to announce the appointment of five individuals to its Board of Directors. These appointments bring a wealth of experience and expertise to the organization as they rally around the mission to continue to educate, celebrate, and empower the industry.

COPENHAGEN, Denmark, July 25, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting two-year clinical efficacy data from its phase 2 trial with lead compound EVX-01 at the European Society for Medical Oncology (ESMO) Congress 2025 to be held in Berlin, Germany, from October 17-21, 2025.